Biotechnology - Celgene Corp.

Filter

Current filters:

Celgene Corp.

Popular Filters

1 to 25 of 96 results

Celgene appoints Wim Souverijns as vice president general manager for UK and Ireland

Celgene appoints Wim Souverijns as vice president general manager for UK and Ireland

11-12-2014

US biotech company Celgene has appointed Wim Souverijns as vice president general manager for the UK…

BiotechnologyBoardroomCelgene Corp.UKUK & Ireland

Licensing deal index shows re-emergence of late-stage deals

Licensing deal index shows re-emergence of late-stage deals

28-10-2014

Licensing deals among biotech companies have recently shown a healthy surge, especially in later stages.

BiotechnologyCelgene Corp.FinancialLicensingMorrisonUK

Celgene third-quarter results beat estimates; ups guidance

Celgene third-quarter results beat estimates; ups guidance

23-10-2014

US biotech major Celgene today reported better-than-expected financial results, with net product sales…

BiotechnologyCelgene Corp.Celgene Corp.FinancialUnited StatesUSA

Sutro Biopharma and Celgene expand accord; add buyout option

23-10-2014

Sutro Biopharma today announced it has entered into a strategic collaboration and option agreement with…

BiotechnologyCelgene Corp.LicensingMergers & AcquisitionsOncologySutro Biopharma

NICE preliminary guidance negative on Celgene’s pomalidomide for multiple myeloma

NICE preliminary guidance negative on Celgene’s pomalidomide for multiple myeloma

15-10-2014

UK medical costs watchdog the National Institute for Health and Care Excellence (NICE) has issued preliminary…

BiotechnologyCelgene Corp.ImnovidOncologyPricingRegulationUK

Celgene gains Swissmedic approval of Abraxane for both metastatic pancreatic and breast cancers

Celgene gains Swissmedic approval of Abraxane for both metastatic pancreatic and breast cancers

25-09-2014

Switzerland-based Celgene International, a wholly-owned subsidiary of US biotech major Celgene, say that…

AbraxaneBiotechnologyCelgene Corp.OncologyRegulationSwitzerland

UK’s NICE recommends Celgene’s Revlimid for myelodysplastic syndromes

UK’s NICE recommends Celgene’s Revlimid for myelodysplastic syndromes

24-09-2014

The UK’s drug watchdog the National Institute for Health and Care Excellence (NICE) has today issued…

BiotechnologyCelgene Corp.OncologyPricingRegulationRevlimidUK

Celgene’s psoriasis drug Otezla gains FDA approval

Celgene’s psoriasis drug Otezla gains FDA approval

24-09-2014

The US Food and Drug Administration has approved biotech major Celgene’s Otezla (apremilast), an oral,…

BiotechnologyCelgene Corp.DermatologicalsOtezlaRegulationUSA

Celgene cancer drug approved for PBS listing in Australia

17-09-2014

Pancreatic cancer drug Abraxane (paclitaxel protein-bound particles for injectable suspension), from…

AbraxaneAustraliaBiotechnologyCelgene Corp.FinancialOncologyPricing

Cost of Abraxane not justified, says NICE in draft guidance for use in pancreatic cancer

Cost of Abraxane not justified, says NICE in draft guidance for use in pancreatic cancer

09-09-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has published new draft…

AbraxaneBiotechnologyCelgene Corp.OncologyPaclitaxelPricingRegulationUK

bluebird bio poised to advance gene therapy pipeline

bluebird bio poised to advance gene therapy pipeline

02-09-2014

US clinical-stage biotech firm bluebird bio is advancing a pipeline focused on gene therapy, a rapidly…

Biotechnologybluebird bioCelgene Corp.OncologyRare diseasesResearch

NICE U-turn on Celgene’s Revlimid for myelodysplastic syndromes

NICE U-turn on Celgene’s Revlimid for myelodysplastic syndromes

20-08-2014

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) has issued final draft…

BiotechnologyCelgene Corp.Myelodysplastic syndromesOncologyPricingRegulationRevlimidUK

Celgene posts strong sales and earnings for 2nd-qtr

24-07-2014

US biotech firm Celgene reported net product sales of $1,845 million for the second quarter of 2014,…

BiotechnologyCelgene Corp.Financial

Celgene's cancer drug Istodax could re-activate dormant HIV and allow it to be detected

Celgene's cancer drug Istodax could re-activate dormant HIV and allow it to be detected

23-07-2014

An anti-cancer drug developed by US biotech company Celgene Corp can re-activate dormant HIV which allows…

Aarhus UniversityAnti-viralsBiotechnologyCelgene Corp.DenmarkHIVHIV/AIDSIsodaxResearchromidepsin

Celgene’s Imnovid now reimbursed in Sweden, Spain and Switzerland

Celgene’s Imnovid now reimbursed in Sweden, Spain and Switzerland

11-07-2014

US biotech firm Celgene’s Imnovid (pomalidomide), called Pomalyst in the USA, is now approved for reimbursement…

BiotechnologyCelgeneFinancialHealthcareImnovidOncologyPomalystSpainSweden

Celgene’s Otezla misses endpoint in Ph III ankylosing spondylitis study

Celgene’s Otezla misses endpoint in Ph III ankylosing spondylitis study

09-07-2014

Shares of US biotech firm Celgene fell 3.5% in premarket trade, but were up 1.2% $86.75 by mid-morning…

Anti-Arthritics/RheumaticsBiotechnologyCelgeneOtezlaResearchUSA

Celgene exercises option for Agios Pharma’s AG-221

Celgene exercises option for Agios Pharma’s AG-221

17-06-2014

Metabolism specialist Agios Pharmaceuticals says that its partner, biotech major Celgene Corp, has exercised…

AG-221Agios PharmaceuticalsBiotechnologyCelgeneLicensingOncologyRegulationResearchUSA

Celgene announce organizational changes to leadership team

Celgene announce organizational changes to leadership team

23-05-2014

US biotech company Celgene Corp (Nasdaq: CELG) has announced organizational changes to its leadership…

BiotechnologyBoardroomCelgeneUSA

NICE draft guidance negative on Celgene’s Revlimid

20-05-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has today issued…

BiotechnologyCelgeneOncologyPricingRegulationRevlimidUK

AADi in-licenses Celgene’s ABI-009

20-05-2014

US clinical-stage biopharma company AADi says it has in-licensed ABI-009 from biotech firm Celgene. Financial…

AADiABI-009BiotechnologyCardio-vascularCelgeneOncologyRespiratory and Pulmonary

Celgene gains rights to Nogra product in potential $1 billion-plus deal

Celgene gains rights to Nogra product in potential $1 billion-plus deal

24-04-2014

US biotech firm Celgene has entered a global license agreement with privately-held Irish company Nogra…

Anti-Arthritics/RheumaticsBiotechnologyCelgeneGED-0301LicensingNogra Pharma

Celgene beats expectations, despite profit downturn

24-04-2014

US biotech firm Celgene saw its shares fall 3.3% to $140.05 in mid-morning trading after it posted first-quarter…

BiotechnologyCelgeneFinancial

1 to 25 of 96 results

Back to top